Loading patent…
AssigneeUniversity of Kansas
InventorsHiroshi Nishimune, Richard Barohn, Buddhadeb Dawn, Yomna Badawi, James W Mitchell, Rupal Soder
Estimating the term…
Embodiments of the present disclosure relate generally to the production of therapeutic mesenchymal stem cells (MSCs). More particularly, the present disclosure relates to the use of cell culture compositions and methods for generating MSCs that secrete neurotrophic factors and synaptic organizing agents for the treatment of neurodegenerative diseases such as Amyotrophic Lateral Sclerosis (ALS). As such, the present disclosure addresses the need for establishing a reliable source of therapeutic stem cells useful for the treatment of neurodegenerative diseases.
An isolated non-genetically modified human cell activated ex vivo from a mesenchymal stem cell (MSC) under conditions such that the isolated non-genetically modified human cell secretes laminin β2 at a level that is greater than the basal secretion level of laminin β2 by the MSC.
A method for producing a cell from a mesenchymal stem cell (MSC), such that the cell secretes laminin β2 at a level that is greater than the basal secretion level of laminin β2 by the MSC, the method comprising:
Dependencies are inferred from the claim text.